Website swissbiotech.org

mondoBIOTECH's medicinal product candidate DasKloster 0039 granted patent for treatment of Hepatitis B virus infection by the US Patent Office

"Hepatitis B virus infections induce an immune response leading to inflammation in the liver (hepatitis), which might also evolve into liver cirrhosis and eventually lead to hepatocellular carcinoma. Our medicinal product candidate has shown efficacy in eradicating the virus, thus reducing the risks of such liver pathologies" says Company’s CSO Dr. Dorian Bevec. Ruggero Gramatica, Chief Executive Officer of mondoBIOTECH holding AG, commented: "We are very pleased to have obtained this particular patent protection that generate another substantial asset to our product pipeline." About mondoBIOTECH mondoBIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE), an independent Swiss biotech company, discovers drugs for patients suffering from rare diseases through its internally developed Search&Match methodology. In Search&Match mondoBIOTECH's scientists combine their unique knowledge of biologically active human peptides with advanced technology solutions delivering medicinal product candidates for rare diseases to licensing partners. Furthermore, mondoBIOTECH has built and is expanding a continuously growing Community of high-level physicians and researchers who dedicate their life to rare diseases. This Rare Community is composed of biologists, biochemists, physicians, patients and patient advocacy organizations as well as other persons and organizations who share their experiences, know-how, expertise and skills with mondoBIOTECH to reach out to people who will benefit the most from an effective treatment, the patients.